You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: October 12, 2024

Investigational Drug Information for INCB050465


✉ Email this page to a colleague

« Back to Dashboard


What is the drug development status for INCB050465?

INCB050465 is an investigational drug.

There have been 32 clinical trials for INCB050465. The most recent clinical trial was a Phase 2 trial, which was initiated on May 26th 2021.

The most common disease conditions in clinical trials are Lymphoma, Neoplasms, and Primary Myelofibrosis. The leading clinical trial sponsors are Incyte Corporation, National Cancer Institute (NCI), and Mayo Clinic.

There are ten US patents protecting this investigational drug and two hundred and eighty-two international patents.

Recent Clinical Trials for INCB050465
TitleSponsorPhase
To Evaluate Efficacy and Safety of Parsaclisib Plus Either Rituximab or Obinutuzumab in R/R Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL) (CITADEL-302)Incyte CorporationPhase 3
Study of the Efficacy and Safety of Parsaclisib in Participants With Primary Warm Autoimmune Hemolytic AnemiaIncyte CorporationPhase 3
IBI376 Plus Rituximab in Patients With Untreated Indolent Lymphoma.Chinese PLA General HospitalPhase 2

See all INCB050465 clinical trials

Clinical Trial Summary for INCB050465

Top disease conditions for INCB050465
Top clinical trial sponsors for INCB050465

See all INCB050465 clinical trials

US Patents for INCB050465

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
INCB050465 ⤷  Sign Up Bicyclic fused pyrimidine compounds as TAM inhibitors Incyte Corporation (Wilmington, DE) ⤷  Sign Up
INCB050465 ⤷  Sign Up Pyrrolopyrimidine derivatives as TAM inhibitors Incyte Corporation (Wilmington, DE) ⤷  Sign Up
INCB050465 ⤷  Sign Up Treatment of B-cell malignancies by a combination JAK and PI3K inhibitors Incyte Corporation (Wilmington, DE) ⤷  Sign Up
INCB050465 ⤷  Sign Up Heterocyclic compounds as PI3K-.gamma. inhibitors Incyte Corporation (Wilmington, DE) ⤷  Sign Up
INCB050465 ⤷  Sign Up Salts and processes of preparing a PI3K inhibitor Incyte Corporation (Wilmington, DE) ⤷  Sign Up
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for INCB050465

Drugname Country Document Number Estimated Expiration Related US Patent
INCB050465 World Intellectual Property Organization (WIPO) WO2017027717 2035-08-12 ⤷  Sign Up
INCB050465 World Intellectual Property Organization (WIPO) WO2017035366 2035-08-26 ⤷  Sign Up
INCB050465 Australia AU2015244044 2034-04-08 ⤷  Sign Up
INCB050465 Australia AU2020213313 2034-04-08 ⤷  Sign Up
INCB050465 Australia AU2022206693 2034-04-08 ⤷  Sign Up
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.